1-20 of 26
Gareth P. Gregory
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CRS-RS.5p predictive model informs risk stratification and cytokine release syndrome management following glofitamab treatment in patients with relapsed or refractory diffuse large B-cell lymphoma

Free
Haifaa Abdulhaq, Linda Lundberg, Anton Belousov, James Relf, Rachel Linacre, Gareth P. Gregory
Journal: Blood
Blood (2025) 146 (Supplement 1): 2559.
https://doi.org/10.1182/blood-2025-2559
Published: 2025
Journal Articles

Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO

Free
Jeremy Abramson, Matthew Ku, Christopher Fox, Huiqiang Huang, Huilai Zhang, William Townsend, Dok Hyun Yoon, Won-Seog Kim, Haifaa Abdulhaq, Charles Herbaux, Jan Zaucha, Hung Chang, Estefania Mulvihill, Murali Kesavan, Martine Joanna Kallemeijn, Richard Ta, Voleak Choeurng, Alessia Bottos, Linda Lundberg, Gareth P. Gregory
Journal: Blood
Blood (2025) 146 (Supplement 1): 5519.
https://doi.org/10.1182/blood-2025-5519
Published: 2025
Journal Articles

Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups

Free
Haifaa Abdulhaq, William Townsend, Matthew Ku, Gareth P. Gregory, Jeremy Abramson, Huiqiang Huang, Huilai Zhang, Dok Hyun Yoon, Won-Seog Kim, Herve Ghesquieres, Mark Hertzberg, Qing-Yuan Zhang, Murali Kesavan, Estefania Mulvihill, Martine Joanna Kallemeijn, Richard Ta, Voleak Choeurng, Linda Lundberg, Christopher Fox
Journal: Blood
Blood (2025) 146 (Supplement 1): 3743.
https://doi.org/10.1182/blood-2025-3743
Published: 2025
Journal Articles

Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated study

Free
Ross Salvaris, Colm Keane, Judith Trotman, Antony Sutherland, Mark Waltham, David Simpson, Gareth P. Gregory, Stephen Opat
Journal: Blood
Blood (2025) 146 (Supplement 1): 1926.
https://doi.org/10.1182/blood-2025-1926
Published: 2025
Journal Articles

Burkitt lymphoma: click here to add to CAR-T?

Free
Eliza A. Hawkes, Gareth P. Gregory
Journal: Blood
Blood (2025) 145 (23): 2678–2680.
https://doi.org/10.1182/blood.2025028549
Published: 2025
Journal Articles

Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress

Free
Maciej Tatarczuch, Colm Keane, Christina Brown, Pratyush Giri, Gavin Cull, Masa Lasica, Charles Shuttleworth, Joel Wight, Marjan Tabesh, Belinda E Butcher, Sze Ting Lee, Eliza A. Hawkes, Gareth P. Gregory
Journal: Blood
Blood (2024) 144 (Supplement 1): 4502.2.
https://doi.org/10.1182/blood-2024-200410
Published: 2024
Journal Articles

Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)

Free
Marina Bacac, Johannes Sam, Won Seog Kim, Gareth P. Gregory, Matthew Ku, Sylvia Herter, Christian Klein, Pablo Umana, Stephen Simko, Victor Orellana-Noia, Linda Lundberg, Alessia Bottos
Journal: Blood
Blood (2024) 144 (Supplement 1): 2990.
https://doi.org/10.1182/blood-2024-200753
Published: 2024
Journal Articles

Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Free
Katharine L. Lewis, Wojciech Jurczak, Gareth P. Gregory, Constantine S. Tam, Won Seog Kim, Eliza A. Hawkes, Franck Morschhauser, Sarit E. Assouline, Geoffrey Shouse, Petra Langerbeins, Monica Tani, Young Rok Do, Bruce D. Cheson, Catherine S. Diefenbach, Craig A. Portell, Jennifer Xavier, Muhtarjan Osman, Siminder K. Atwal, Wan-Jen Hong, Clémentine Sarkozy
Journal: Blood
Blood (2024) 144 (Supplement 1): 4501.
https://doi.org/10.1182/blood-2024-199281
Published: 2024
Journal Articles

Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study

Free
Gareth P. Gregory, Jeremy S. Abramson, Hui-Qiang Huang, Qing-Yuan Zhang, Matthew Ku, Dok Hyun Yoon, Christopher P. Fox, Haifaa Abdulhaq, William Townsend, Joan Ashby, Alana Harris, Victor Orellana-Noia, Stephen Simko, Martine Kallemeijn, Richard Ta, James Relf, Huang Huang, Linda Lundberg, Huilai Zhang
Journal: Blood
Blood (2024) 144 (Supplement 1): 5132.
https://doi.org/10.1182/blood-2024-198424
Published: 2024
Journal Articles

A Phase 1 Study Evaluating PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Select Relapsed/Refractory B-Cell Malignancies

Free
Bruce D. Cheson, Geoffrey P. Shouse, Sarit Assouline, Katharine L. Lewis, Eliza A Hawkes, Talha Munir, Andrew S. Davies, Petra Langerbeins, Constantine S. Tam, Gareth P. Gregory, Michael Y. Choi, William Sun, Siminder K. Atwal, Wan-Jen Hong, Clémentine Sarkozy
Journal: Blood
Blood (2023) 142 (Supplement 1): 6324.
https://doi.org/10.1182/blood-2023-182434
Published: 2023
Journal Articles

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Free
Armando Santoro, Nathalie A. Johnson, Kerry J. Savage, Abraham Avigdor, Ali Bazargan, Peter Borchmann, Robin Gasiorowski, Gareth P. Gregory, Yair Herishanu, Sumit Madan, Leonard Minuk, Gerardo Musuraca, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Pier Luigi Zinzani
Journal: Blood
Blood (2023) 142 (Supplement 1): 1725.
https://doi.org/10.1182/blood-2023-182536
Published: 2023
Journal Articles

Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Free
John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tzoran, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Alex F. Herrera
Journal: Blood
Blood (2023) 142 (Supplement 1): 4440.
https://doi.org/10.1182/blood-2023-182019
Published: 2023
Journal Articles

Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Free
Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, John Timmerman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1693.
https://doi.org/10.1182/blood-2023-182128
Published: 2023
Journal Articles

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Free
Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, John Palcza, Pallavi Pillai, Akash Nahar, John Timmerman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6540–6542.
https://doi.org/10.1182/blood-2022-166846
Published: 2022
Journal Articles

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment

Free
John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tsoran-Rosenthal, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Akash Nahar, Alex F. Herrera
Journal: Blood
Blood (2022) 140 (Supplement 1): 768–770.
https://doi.org/10.1182/blood-2022-166670
Published: 2022
Journal Articles

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

Free
Genevive H. Hernandez, John So, Kathryn A. Logronio, Maya F. Kotturi, Won Seog Kim, Philippe Armand, Chan Y. Cheah, Ajay K. Gopal, Ian W. Flinn, Gareth P. Gregory, Matthew J. Matasar, Loretta J. Nastoupil, Catherine S. Diefenbach, Sung-Soo Yoon, Matthew Ku, Ibrahim Qazi, Maya K. Leabman, Iris Sison, Bruce A. Keyt, Chris H. Takimoto, Thomas J. Manley, Elizabeth L. Budde
Journal: Blood
Blood (2022) 140 (Supplement 1): 6436–6438.
https://doi.org/10.1182/blood-2022-163235
Published: 2022
Journal Articles

A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies

Free
Elizabeth Budde, Ajay K Gopal, Won Seog Kim, Ian W. Flinn, Chan Yoon Y. Cheah, Loretta Nastoupil, Matthew J. Matasar, Catherine S. Diefenbach, Gareth P Gregory, Ibrahim Qazi, Ching-Fai Pang, Maya Leabman, Genevive Hernandez, Iris Sison, Bruce A. Keyt, Daniel Chen, Philippe Armand
Journal: Blood
Blood (2021) 138 (Supplement 1): 132.
https://doi.org/10.1182/blood-2021-153355
Published: 2021
Journal Articles

Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA)

Free
Maciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, Briony Shaw, Michelle Poon, Erin Paul, Matthew Ku, Mark Wong, Ashley Beekman, Michael Krigstein, Pietro R Di Ciaccio, Joel Wight, Caitlin Coombes, Michael Gilbertson, Amanda Tey, Jake Shortt, Chandramouli Nagarajan, Maya Latimer, Dipti Talaulikar, Nada Hamad, Sumita Ratnasingam, Tara Cochrane, Eliza Hawkes, Chan Yoon Cheah, Stephen Opat, Gareth P Gregory
Journal: Blood
Blood (2021) 138 (Supplement 1): 2532.
https://doi.org/10.1182/blood-2021-145959
Published: 2021
Journal Articles

High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients

Free
Katharine Louise Lewis, Lasse H. Jakobsen, Diego Villa, Sabela Bobillo, Karin Ekstroem Smedby, Kerry J. Savage, Toby A. Eyre, Kate Cwynarski, Paris L Caporn, Joan Van Zyl, Magdalena Klanova, Marek Trněný, Robert Puckrin, Douglas A. Stewart, Mark J Bishton, Christopher P. Fox, Aung M Tun, Gita Thanarajasingam, Faouzi Djebbari, Erel Joffe, Sandra Eloranta, Sara Harrysson, Laurie H. Sehn, Seth M Maliske, Kittika Poonsombudlert, Xiao Guo, Greg Hapgood, Kate Manos, Eliza Hawkes, Jahanzaib Khwaja, Adrian Minson, Michael Dickinson, Andreas Kiesbye Øvlisen, Gareth P Gregory, Michael Gilbertson, Isaac T Streit, Hamish W Scott, Matthew Ku, Sanjay de Mel, Kar Ying Yong, Liu Xin, Mridula Mokoonlall, Dipti Talaulikar, Nicholas L McVilly, Anna Johnston, Matthew J Brunner, Priyanka A Pophali, Matthew J. Maurer, Tarec Christoffer El-Galaly, Chan Yoon Cheah
Journal: Blood
Blood (2021) 138 (Supplement 1): 181.
https://doi.org/10.1182/blood-2021-146737
Published: 2021
Journal Articles

Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance

Free
Pietro R Di Ciaccio, Belinda Campbell, Kylie D Mason, Mohamed Shanavas, Matthew Greenwood, Gareth P Gregory, Renee Eslick, Giselle Kidson-Gerber, Catherine Tang, Kirk L Morris, Portia Smallbone, Xavier Badoux, Michael J Shipton, Sean J McKeague, Jenna Langfield, Kathryn Goss, Nada Hamad
Journal: Blood
Blood (2021) 138 (Supplement 1): 882.
https://doi.org/10.1182/blood-2021-150538
Published: 2021